Lifecore Biomedical (LFCR) has been notified by Nasdaq that the company’s stock is expected to be added to the Nasdaq Biotech Index (NBI) as part of the annual reconstitution of the 2025 Nasdaq indexes. Lifecore’s inclusion in the Nasdaq Biotech Index will be effective prior to market open on Monday, December 22, 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- Lifecore signs CDMO master services agreement with pharma customer
- Cautious Hold Rating on Lifecore Biomedical Amid Operational Progress and Financial Risks
- Optimistic Outlook for Lifecore Biomedical: Strategic Growth and Financial Stability
- Lifecore Biomedical Reports Strong Revenue Growth
- Lifecore backs transition period revenue view $74M-$76M